bioRxiv Science⌕ Search

bioRxiv · 10.1101/2022.06.20.496877

Bayesian Hierarchical Model for Immune Responses to Leishmania - a tick borne Co-Infection Study

Abstract

While many Bayesian state-space models for infectious disease processes focus on population infection dynamics (e.g., compartmental models), in this work we examine the evolution of infection processes and the complexities of the immune responses within the host using these techniques. We present a joint Bayesian state-space model to better understand how the immune system contributes to the control of Leishmania infantum infections over the disease course. We use longitudinal molecular diagnostic and clinical data of a cohort of dogs to describe population progression rates and present evidence for important drivers of clinical disease. Among these results, we find evidence for the importance of co-infection in disease progression. We also show that as dogs progress through the infection, parasite load is influenced by their age, ectoparasiticide treatment status, and serology. Furthermore, we present evidence that pathogen load information from an earlier point in time influences its future value and that the size of this effect varies depending on the clinical stage of the dog. In addition to characterizing the processes driving disease progression, we predict individual and aggregate patterns of Canine Leishmaniasis progression. Both our findings and the application to individual-level predictions are of direct clinical relevance, presenting possible opportunities for application in veterinary practice and motivating lines of additional investigation to better understand and predict disease progression. Finally, as an important zoonotic human pathogen, these results may support future efforts to prevent and treat human Leishmaniosis. 1 AUTHOR SUMMARYThe immune system is a complex network that involves organs, cells, and proteins working together with the main purpose of protecting the body against harmful microorganisms such as bacteria, viruses, fungi, and toxins. To explore and study the responses of the host immune system during the course of a disease, we modeled the interaction between pathogen load, antibody responses, and the clinical presentation of this complex system. Specifically, we focused on Canine Leishmaniasis (CanL), a vector-borne disease caused by a parasite that affects internal organs of the body and is known to be fatal if patients remain untreated. In addition, we also considered the impact of possible co-infections with other diseases, which could potentially interact with many disease processes and contribute to different outcomes for infected subjects. With CanL specifically, we consider the presence of Borrelia, Anaplasma, Ehrlichia,, and Heartworm. In general, one limitation in vaccination strategies is a focus on neutralizing antibodies, without incorporating the broader complexities of immune responses. Here, we explore this complexity by jointly considering the interaction between pathogen and antibody development with the purpose of improving our understanding of the processes of disease progression and natural immunity. In this paper, we present a Bayesian model specification for immune responses to a Leishmania infection considering a tick-borne co-infection study. The model implementation is based on the general vector autoregressive (VAR) model, adapted to the problem under study. While the methodology around Bayesian VAR models is not new in the literature, in this work we adapt the more general VAR approach in a parsimonious way to a particular subclass of longitudinal problems. We believe our defined Bayesian model is useful to clinicians and veterinarians to better understand the immune responses and Leishmania infection control over time, which makes this work a novel application of Bayesian VAR models. We present evidence that pathogen load information from an earlier point in time influences its future value and that the size of this effect varies depending on the CanL clinical stage of the dog. In addition to characterizing evidence for the processes driving disease progression, we predict individual and aggregate patterns of CanL progression. The structure of this paper starts in Section 2 with an introduction to CanL infection as well as a discussion of possible co-infection with other pathogens. In Section 3, we include a description of the motivating prospective study along with the measured individual-level variables, a definition of the clinical signs of leishmaniosis infection, and a description of the available data coming from the study. In addition, this section explains the dynamic process and corresponding model specification via Bayesian methodology and a statement of contribution. A summary of prior distributions for model parameters, model implementation details, and convergence diagnostics are also included. In Section 4, we provide summary results from the posterior distribution as well as a summary of the corresponding disease progression forecasts. In Section 5, we discuss the results and describe future considerations to improve and extend the model.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Pabon-Rodriguez, F. M., Brown, G. D., Scorza, B. M., Petersen, C. A.. 2022-06-20. Bayesian Hierarchical Model for Immune Responses to Leishmania - a tick borne Co-Infection Study. https://doi.org/10.1101/2022.06.20.496877

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

De novo design of CR2 binder as vaccine scaffold

Efficient B cell activation during vaccine-induced humoral immunity relies on both B cell receptor (BCR) antigen recognition and synergistic signaling from co-receptors. Complement receptor 2 (CR2), the primary BCR co-receptor on B cells, lowers the activation threshold and amplifies downstream kinase signaling by orders of magnitude when engaged by complement fragment C3d decorated antigens. Targeting CR2 therefore represents a rational vaccine enhancement strategy, yet native C3d suffers from low affinity, poor stability, and manufacturing challenges. Here, we report the de novo design of a highly stable, high-affinity CR2 binder using deep learning driving protein design methods. Biophysical characterization, high-resolution cryoEM structural determination, and functional assays in vitro and in vivo confirm that the designed binder matches computational design models and specifically engages CR2 to boost B cell activation. When fused to antigen as a vaccine scaffold, the trimeric CR2 binder elicits robust humoral immune responses comparable to nanoparticle vaccines, while retaining the simplicity of single-chain protein production. Our work establishes a modular CR2 targeting vaccine scaffold platform with broad translational potential for next-generation protein vaccines.

immunology↗

Chronic opioid-associated immune dysregulation among people living with HIV

Objectives: Persistent immune dysregulation contributes to chronic disease among people living with HIV (PWH), even after viral suppression with antiretroviral therapy (ART). Although chronic opioid exposure is associated with adverse clinical outcomes, its impact on immune homeostasis during ART remains incompletely understood. We investigated whether opioid use disorder (OUD) is associated with persistent systemic and cellular immune dysregulation despite ART-mediated reductions in HIV viral load (VL). Methods: Peripheral blood was collected longitudinally from PWH with OUD (PWH/OUD+) and detectable HIV VL during 6 months of optimized ART (months 0, 3, and 6). A reference cohort of PWH without OUD (PWH/OUD-) and suppressed HIV VL provided a single blood sample. Immune profiling included plasma inflammatory biomarkers, multiplex cytokine analyses, spectral flow cytometry, and assessment of monocyte cytokine responses following lipopolysaccharide (LPS) stimulation. Mixed-effects models adjusted for HIV VL and VL-stratified analyses were performed. Results: PWH/OUD+ exhibited persistent immune dysregulation despite reductions in HIV VL. Plasma sCD163, sCD14, fractalkine, and I-TAC remained elevated, whereas TGF-{beta}1 was reduced. OUD was associated with expansion of CD16 monocytes and altered expression of CCR2, CD38, and CD11b. CD4 and CD8 T cells, NK cells, and B cells also exhibited persistent alterations in markers of activation, metabolism, and trafficking. Monocytes from PWH/OUD+ displayed attenuated cytokine responses following LPS stimulation. Conclusions: OUD is associated with persistent systemic and cellular immune dysfunction in PWH despite ART-mediated viral suppression, supporting opioid exposure as an independent contributor to chronic immune dysregulation that may promote inflammation, immune dysfunction, and long-term HIV-associated comorbidities. Keywords: HIV, Opioid-use disorder, innate immunity, cytokine

immunology↗

The mitochondrial RNA extrusion-induced innate immunity is regulated by N6-methyladenosine machinery

Mitochondrial RNA (mtRNA) released into the cytosol functions as a damage associated molecular pattern that activates pattern-recognition receptor (PRR)-mediated inflammation, yet its release mechanisms and cytoplasmic fate remain poorly understood. Here we report that chemical Abt-373-treatment and Vesicular stomatitis virus (VSV) infection induce mtRNA extrusion through Bax/Bak and VDAC1 channels, accompanied by mtDNA release. Extruded mtRNA in A549 cells activates multiple cytosolic PRRs, including RIG-I, MDA5, TLR3/7/8, and PKR, each contributing differentially to the innate immune signaling. Analysis of GEO datasets and methylated RNA immunoprecipitation (MeRIP) assays further reveals that mtRNA carries methyladenosine (m6A) modification. m6A machinery proteins are involved in the cytoplasmic retention time of mtRNA and its interaction with RIG-I, thereby modulating mtRNA-induced innate immunity. Thus, our work establishes in vitro models of mtRNA extrusion, and highlights m6A-dependent modulation as a potential therapeutic target for mtRNA-driven inflammation.

immunology↗